or Try an Advanced Search...

    Technical Analysis for CTMX - CytomX Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.85 -2.83% -0.02
    CTMX closed down 2.53 percent on Wednesday, November 20, 2024, on 50 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CTMX trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness -2.83%
    Below Lower BB Weakness -2.83%
    Lower Bollinger Band Touch Weakness -2.83%
    Oversold Stochastic Weakness -2.83%
    Stochastic Buy Signal Bullish -5.29%
    Lower Bollinger Band Walk Weakness -5.29%
    New 52 Week Low Weakness -5.29%
    Lower Bollinger Band Touch Weakness -5.29%
    Oversold Stochastic Weakness -5.29%
    New 52 Week Closing Low Bearish -2.05%
    Older End-of-Day Signals for CTMX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Lower Bollinger Band about 2 hours ago
    Down 3% about 2 hours ago
    Fell Below Previous Day's Low about 2 hours ago
    Down 2 % about 2 hours ago
    Down 1% about 2 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CTMX Chart by TradingView
    Basic chart:

    Profile

    CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Life Sciences Compugen Monoclonal Antibody Therapy Immunogen Oncology Focused Biopharmaceutical

    Is CTMX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 6 CytomX Q3 2024 Earnings Preview
    Oct 31 CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
    Sep 9 CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
    Sep 4 CytomX Therapeutics to Present at Upcoming September Investor Conferences
    Aug 10 CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
    Aug 9 CytomX Therapeutics files $250M mixed securities shelf
    Aug 9 CytomX Therapeutics, Inc. (CTMX) Q2 2024 Earnings Call Transcript
    Aug 8 CytomX Therapeutics: Q2 Earnings Snapshot
    Aug 8 CytomX GAAP EPS of -$0.08 misses by $0.01, revenue of $25.11M beats by $5.12M
    Aug 8 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    See more CTMX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.85
    52 Week Low 0.833
    Average Volume 865,156
    200-Day Moving Average 1.59
    50-Day Moving Average 1.10
    20-Day Moving Average 0.99
    10-Day Moving Average 0.97
    Average True Range 0.07
    RSI (14) 31.97
    ADX 19.96
    +DI 13.11
    -DI 26.84
    Chandelier Exit (Long, 3 ATRs) 0.95
    Chandelier Exit (Short, 3 ATRs) 1.04
    Upper Bollinger Bands 1.12
    Lower Bollinger Band 0.87
    Percent B (%b) 0.0
    BandWidth 24.81
    MACD Line -0.06
    MACD Signal Line -0.04
    MACD Histogram -0.0122
    Fundamentals Value
    Market Cap 58.29 Million
    Num Shares 67 Million
    EPS -0.15
    Price-to-Earnings (P/E) Ratio -5.80
    Price-to-Sales 1.07
    Price-to-Book 5.04
    PEG Ratio -1.80
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.97
    Resistance 3 (R3) 0.98 0.95 0.96
    Resistance 2 (R2) 0.95 0.92 0.95 0.95
    Resistance 1 (R1) 0.91 0.91 0.90 0.90 0.94
    Pivot Point 0.88 0.88 0.87 0.88 0.88
    Support 1 (S1) 0.84 0.85 0.83 0.84 0.80
    Support 2 (S2) 0.81 0.84 0.81 0.79
    Support 3 (S3) 0.77 0.81 0.78
    Support 4 (S4) 0.77